Log In
    ZOMDF
    $0.1
    (2.18%)
    FLWS
    $3.19
    (2.9%)
    ACCO
    $3.42
    (-1.72%)
    ARLP
    $24.98
    (-0.08%)
    AUIAF
    $0.1
    (-0.7%)
    AZZ
    $98.14
    (0.51%)
    BTBT
    $2.41
    (-4.37%)
    BTM
    $2.04
    (-1.45%)
    CVKD
    $11.61
    (-0.34%)
    LCE:CA
    $0.25
    (-3.85%)
    COCP
    $1.03
    (0%)
    CDRO
    $5.69
    (4.79%)
    CVGI
    $1.53
    (-1.92%)
    LODE
    $2.97
    (4.21%)
    CMTL
    $3.2
    (-0.62%)
    CNDT
    $2.05
    (1.99%)
    CXW
    $17.19
    (2.63%)
    CMLS
    $0.1
    (-11.54%)
    DRCT
    $0.2
    (-29.47%)
    DLHC
    $5.98
    (2.22%)
    SSP
    $3.06
    (-2.24%)
    ELDN
    $1.76
    (0%)
    EVC
    $2.85
    (-0.35%)
    EDRY
    $13.05
    (-1.32%)
    ESEA
    $59.73
    (-0.76%)
    FAT
    $1.36
    (0.74%)
    RAIL
    $8.23
    (-2.02%)
    GDEV
    $20.6
    (-6.37%)
    GOVX
    $0.45
    (-3.82%)
    GOCO
    $2.54
    (-2.69%)
    GHM
    $59
    (1.46%)
    GLDD
    $12.35
    (-1.28%)
    GYRE
    $7.41
    (0.27%)
    HMENF
    $1.54
    (2.15%)
    III
    $5.25
    (0%)
    IPOOF
    $9.15
    (-0.14%)
    KELYA
    $8.34
    (-4.36%)
    KTOS
    $72.45
    (1.06%)
    LUCK
    $8.11
    (-3.57%)
    MAIA
    $1.04
    (2.97%)
    MGROF
    $0.45
    (-1.02%)
    NTRB
    $5.5
    (-2.48%)
    OCGN
    $1.19
    (-4.03%)
    PERF
    $1.84
    (1.1%)
    QMCI
    $0.13
    (-19.15%)
    RGP
    $4.8
    (4.8%)
    SGA
    $12.01
    (-1.4%)
    SHWZ
    $0
    (0%)
    SHIP
    $9.37
    (1.52%)
    SLQT
    $1.49
    (-4.49%)
    SKYX
    $1.79
    (16.99%)
    SNAL
    $0.92
    (-5.64%)
    GEO
    $15.22
    (4.39%)
    ODP
    $27.87
    (0.07%)
    TNXP
    $15.9
    (-1.55%)
    TSQ
    $5.17
    (-4.79%)
    TZOO
    $7.25
    (-2.29%)
    UNCY
    $5.67
    (6.38%)
    VVX
    $54.24
    (-0.18%)
    VNCE
    $2.47
    (-8.52%)
    XELB
    $0.85
    (-11.92%)
    ZOMDF
    $0.1
    (2.18%)
    FLWS
    $3.19
    (2.9%)

    channelchek-in

    ‌
    11/14/2025

    Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal, Strengthening Its Antiviral Pipeline

    Merck has announced a major expansion of its infectious disease portfolio with a definitive agreement to acquire Cidara Therapeutics, Inc. for approximately $9.2 billion. The all-cash transaction, valued at $221.50 per share, brings Cidara’s late-stage antiviral candidate CD388 directly into Merck’s pipeline as the company seeks to diversify its portfolio with innovative, long-acting preventative treatments.

    0
    3 min read
    • ‌
      Noble Capital Markets Research Morning Call

      Noble Capital Markets Research Morning Call

      Today’s Noble Capital Markets equity research reports, available with free...

      63 min read

    • Redefining What You Should Expect From Your Accountant

      3 min read

    • Receive FREE Research, News, Video, and Event Updates in Your Inbox!

    • Tesla Stock Rebounds as Investors Refocus on Long-Term AI and Robotics Vision

      3 min read
    View all

    News

    11/14/2025

    Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal, Strengthening Its Antiviral Pipeline

    3 min read
    ‌
    Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal, Strengthening Its Antiviral Pipeline
    11/14/2025

    Release – Bit Digital, Inc. Announces Financial Results for the Third quarter of Fiscal Year 2025

    8 min read
    ‌
    Release – Bit Digital, Inc. Announces Financial Results for the Third quarter of Fiscal Year 2025
    11/14/2025

    Release – Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    12 min read
    ‌
    Release – Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
    11/14/2025

    Release – The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

    7 min read
    ‌
    Release – The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
    View all

    Research Reports

    The Oncology Institute, Inc. (TOI) – Guidance Raised After 3Q25 Revenues Beat ExpectationsOIISeanergy Maritime (SHIP) – Third Quarter Results Exceed Expectations; Increasing EstimatesSM(Newsmax (NMAX) – Executing On Its Growth StrategyN(EGoHealth (GOCO) – Reset in Progress as Carriers RecalibrateG(R
    View all

    Video Content

  • ‌
    First Phosphate Corp.

    First Phosphate Corp.

    Conference Presentation
    10/9/2025
  • ‌
    SKYX Platforms Corp.

    SKYX Platforms Corp.

    Conference Presentation
    10/9/2025
  • ‌
    DHI Group Inc.

    DHI Group Inc.

    Conference Presentation
    10/9/2025
  • ‌
    Birchtech Corp

    Birchtech Corp

    Conference Presentation
    10/9/2025
    • View all

    Movers

    Symbol
    Change
    CDTX
    105.41%
    ROCK:CA
    36.76%
    IVVD
    32.77%
    TOI
    28.9%
    CNTB
    26.19%
    View all
    Log In